

## Limited Submission Funding Opportunities – updated 6/03/22

Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of \$50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at [ecor@mgh.harvard.edu](mailto:ecor@mgh.harvard.edu)

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

### Process

Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to [ecor@mgh.harvard.edu](mailto:ecor@mgh.harvard.edu). In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:

1. Name of the Principal Investigator with appropriate contact information
2. A descriptive title of the potential application
3. Brief description of the project
4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at [ecor@mgh.harvard.edu](mailto:ecor@mgh.harvard.edu).

### CURRENT OPPORTUNITIES

1. **NICHD Neonatal Research Network (NRN): Data Coordinating Center (U24 Clinical Trial Optional)**  
<https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-23-001.html>

**MGH LOI Deadline: 6/14/22**

NIH LOI Deadline: 7/11/22

NIH Application Deadline: 8/11/22

The *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) invites institutions to submit applications to participate in the Neonatal Research Network (NRN).

This Funding Opportunity Announcement (FOA) invites applications for a NRN Data Coordinating Center; a separate FOA invites applications for NRN Clinical Centers.

## Limited Submission Funding Opportunities – updated 6/03/22

### 2. NICHD Neonatal Research Network (NRN): Clinical Centers (UG1 Clinical Trial Optional)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-23-002.html>

**MGH LOI Deadline: 6/14/22**

NIH LOI Deadline: 7/11/22

NIH Application Deadline: 8/11/22

The *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) invites institutions to submit applications to participate in the Neonatal Research Network (NRN).

This Funding Opportunity Announcement (FOA) invites applications for NRN Clinical Centers; a separate FOA invites applications for a NRN Data Coordinating Center.

### 3. NICHD Maternal-Fetal Medicine Units (MFMU) Network: Clinical Centers (UG1 Clinical Trial Optional)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-23-016.html>

**MGH LOI Deadline: 6/14/22**

NIH LOI Deadline: 7/11/22

NIH Application Deadline: 8/11/22

The *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) invites institutions to submit applications to participate in the Maternal-Fetal Medicine Units (MFMU) Network.

This Funding Opportunity Announcement (FOA) invites applications for MFMU Network Clinical Centers; a separate FOA invites applications for a MFMU Network Data Coordinating Center.

### 4. NICHD Maternal-Fetal Medicine Units (MFMU) Network: Data Coordinating Center (U24 Clinical Trial Optional)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-AR-23-002.html>

**MGH LOI Deadline: 6/14/22**

NIH LOI Deadline: 7/11/22

NIH Application Deadline: 8/11/22

The *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) invites institutions to submit applications to participate in the Maternal-Fetal Medicine Units (MFMU) Network.

This Funding Opportunity Announcement (FOA) invites applications for a MFMU Network Data Coordinating Center; a separate FOA invites applications for MFMU Network Clinical Centers.

## Limited Submission Funding Opportunities – updated 6/03/22

### 5. NIAMS Rheumatic Diseases Research Resource-based Centers (P30 – Clinical Trial Not Allowed)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-AR-23-002.html>

**MGH LOI Deadline: 7/12/22**

NIH LOI Deadline: 8/13/22

NIH Application Deadline: 9/13/22

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) requests applications for the NIAMS Resource-based Centers Program (P30) for rheumatic diseases research areas within its mission. The Resource-based Centers will provide critical research infrastructure, shared facilities, services, and/or resources to groups of investigators conducting research on rheumatic diseases, enabling them to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively, with the broad overall goal of accelerating, enriching, and enhancing the effectiveness of ongoing basic, translational, and clinical research and promoting new research within the NIAMS mission.